Answers are grounded in this paper and cite their sources.
Novel strategy achieves efficient chiral δ-caprolactam synthesis, indicating potential for scalable production.
Chiral δ-caprolactam constitutes the key pharmacophore of Calcitonin gene-related peptide receptor antagonists such as ubrogepant and atogepant, and its synthesis is quite challenging. Herein, we report a novel, robust, and potentially scalable asymmetric synthesis strategy for chiral δ-caprolactam. The δ-caprolactam scaffold is first constructed via a one-pot process, followed by sequential installation of three stereocenters through crystallization-induced dynamic kinetic resolution and catalytic hydrogenation. This protocol offers distinct advantages, including the absence of enzymatic catalysis and column chromatography.
No takes yet. Share an insight, caveat, or question.
Shi et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: